Company Monitoring Page for Regeneron

latest headlines for company on cafepharma

Safety setback for Pfizer, Lilly pain drug should have Regeneron and Teva feeling nervous
Biopharma Dive
Mon, 04/22/19 - 03:37 pm
Tags:
Pfizer, Eli Lilly, painkillers, tanezumab, Regeneron, Teva Pharmaceutical, fasinumab
Regeneron, Alnylam spell out a research alliance that could run beyond a decade, with billions built in for success
Endpoints
Thu, 04/11/19 - 10:11 am
Tags:
Regeneron, Alnylam, R&D
Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases
Xconomy
Mon, 04/8/19 - 09:56 am
Tags:
Alnylam, Regeneron, RNAi, eye health, brain diseases
FDA approves Dupixent for atopic dermatitis in adolescents
BioCentury
Mon, 03/11/19 - 10:15 pm
Tags:
Dupixent, Regeneron, Sanofi, FDA, atopic dermatitis
Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps
Pharmaforum
Tue, 02/26/19 - 11:48 pm
Tags:
Sanofi, Regeneron, Dupixent, clinical trials, nasal polyps
Regeneron touts one-year diabetic retinopathy data for Eylea
Drug Delivery Business News
Mon, 02/11/19 - 11:44 pm
Tags:
Regeneron, Eylea, proliferative diabetic retinopathy
Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen
Biopharma Dive
Mon, 02/11/19 - 12:23 pm
Tags:
Regeneron, Sanofi, Amgen, Praluent, Repatha, drug pricing, PCSK9 inhibitors
Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer
Endpoints
Fri, 02/8/19 - 11:40 am
Tags:
Regeneron, Merck, Bristol-Myers Squibb, PD-1/L1 therapy, Libtayo, Keytruda, Opdivo, non-small cell lung cancer
Successful launch bolsters Libtayo's place as cornerstone therapy for Regeneron
Biopharma Dive
Wed, 02/6/19 - 03:57 pm
Tags:
Regeneron, Libtayo, earnings, CSCC, drug launches
Report: five companies would take brunt of Trump Part B proposal
BioCentury
Fri, 02/1/19 - 11:24 am
Tags:
Donald Trump, Medicare Part B, Amgen, Regeneron, Bristol-Myers Squibb, Genentech, Roche
Is the Smoldering NASH Market Ready to Burst Into Flames?
BioSpace
Tue, 01/22/19 - 11:52 am
Tags:
NASH, Allergan, Regeneron, Alnylam, AstraZeneca, Merck, Takeda, Gilead Sciences, Bristol-Myers Squibb, Intercept Pharmaceuticals
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
BioSpace
Wed, 01/9/19 - 09:40 am
Tags:
JPMHC 2019, M&A, Eli Lilly, Loxo Oncology, SAGE Therapeutics, Sanofi, Regeneron, Bristol-Myers Squibb, Celgene, Novartis, Gilead Sciences
Sanofi pays Regeneron $462M to exit immuno-oncology R&D pact
Fierce Biotech
Mon, 01/7/19 - 10:10 am
Tags:
Sanofi, Regeneron, immuno-oncology
7 drugs that raised eyebrows in Q3
Biopharma Dive
Thu, 11/15/18 - 11:50 pm
Tags:
Sanofi, Dupixent, Roche, Herceptin, AbbVie, Humira, Regeneron, Repatha, Clovis Oncology, Rubraca, GSK, Shingrix, Eli Lilly, Trulicity
Going gangbusters in atopic dermatitis, the FDA hands Sanofi and Regeneron a fresh coup for their mega-blockbuster star Dupixent
Endpoints
Tue, 11/6/18 - 09:48 am
Tags:
Sanofi, Regeneron, Dupixent, atopic dermatitis
Early November Brings More Quarterly Reports
BioSpace
Sun, 11/4/18 - 02:38 pm
Tags:
earnings, Akcea, Mylan, Eli Lilly, Regeneron
Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab
Endpoints
Mon, 10/29/18 - 10:27 am
Tags:
Roche, Genentech, Regeneron, Novartis, Eylea, faricimab, wet-AMD
Regeneron and Roche Duke it Out in the Diabetic Retinopathy Market
BioSpace
Thu, 10/25/18 - 11:43 am
Tags:
Regeneron, Eylea, diabetic retinopathy, Roche, Lucentis
FDA kicks Regeneron’s latest Eylea application to the curb, but they’re not sweating it
Endpoints
Thu, 10/25/18 - 09:56 am
Tags:
Regeneron, FDA, Eylea, complete response letter
Regeneron, Sanofi talks up potential blockbuster franchise as Dupixent sweeps in rhinosinusitis PhIII
Endpoints
Tue, 10/16/18 - 11:44 am
Tags:
Regeneron, Sanofi, Dupixent, nasal polyps, rhinosinusitis

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.